Targeted immunotherapy for high-risk neuroblastoma-The role of monoclonal antibodies;Inmunoterapia dirigida para el neuroblastoma de alto riesgo: El papel de los anticuerpos monoclonales

Annals of Pharmacotherapy

Volumn 47, Issue 2, 2013, Pages 210-218

  Parsons, Kerry ^a   Bernhardt, Brooke ^b   Strickland, Brandy ^c  

^a Children's of Alabama   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

^c WAKE FOREST BAPTIST HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3F8 MURINE MONOCLONAL ANTIBODY; ADRENALIN; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; BETA DEXTRO GLUCAN; CARBOPLATIN; CH14.18 CHIMERIC ANTIBODY; CISPLATIN; CYCLOPHOSPHAMIDE; DISIALOGANGLIOSIDE ANTIBODY; DOPAMINE; DOXORUBICIN; ETOPOSIDE; HU14.18 INTERLEUKIN 2 MONOCLONAL ANTIBODY; HU14.18K22A MONOCLONAL ANTIBODY; INDOMETACIN; ISOTRETINOIN; MELPHALAN; MONOCLONAL ANTIBODY; OPIATE; PARACETAMOL; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG;

ACCOMMODATION PARALYSIS; ANAPHYLAXIS; ANEMIA; ARTHRALGIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPNEA; FACE EDEMA; FEVER; HIGH RISK PATIENT; HUMAN; HYPERBILIRUBINEMIA; HYPERSENSITIVITY; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; LEUKOCYTE; MACULOPAPULAR RASH; MELANOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYDRIASIS; NAUSEA AND VOMITING; NEUROBLASTOMA; NEUTROPENIA; NEUTROPHIL; PAIN; PRIORITY JOURNAL; RESPIRATORY DISTRESS; REVIEW; SERUM SICKNESS; SIDE EFFECT; STRIDOR; THROMBOCYTE; THROMBOCYTOPENIA; TREATMENT RESPONSE; URTICARIA; VISUAL DISORDER; VOMITING; WHEEZING;

EID: 84873951706     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R353     Document Type: Review

References (47)

1. Davidoff AM. Neuroblastoma. Semin Pediatr Surg 2012;21:2-14.
2. Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am 2010;24:65-86.
3. Cancer Facts & Figures 2012. Atlanta, GA: American Cancer Society, 2012:12.
4. Matthay KK, Villablanca JG, Seeger RD, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999;341: 1165-73.
5. George RE, Diller L, Berstein ML Pharmacotherapy of neuroblastoma. Expert Opin Pharmacother 2010;11:1467-78.
6. Modak S, Cheung NK. Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Invest 2007;25:67-77.
7. Dallegri F, Ballestrero L, Ottonello L, et al. Defective antibody-dependent tumour cell lysis by neutrophils from cancer patients. Clin Exp Immunol 1989;77:58-61.
8. Baxevanis CN, Tsavaris NB, Papadhimitriou SI, et al. Granulocytemonocyte colony stimulating factor improves immunological parameters in patients with refractory solid tumors receiving second-line chemotherapy: correlation with clinical responses. Eur J Cancer 1997;33:1202-8.
9. Hank JA, Robinson RR, Surfus J, et al. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin-2. Cancer Res 1990;50:5234-9.
10. Cheung IY, Hsu K, Cheung NK. Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2012;30:426-32.
11. Cheung NK, Sowers R, Vickers AJ, et al. FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. J Clin Oncol 2006;24:2885-90.
12. Delgado DC, Hank JA, Kolesar J, et al. Genotypes of NK cell KIR receptors, their ligands, and Fcgamma receptors in the response of neuroblastoma patients to hu14.18-IL2 immunotherapy. Cancer Res 2010;70:9554-61.
13. Cheung NK, Saarinen UM, Neeley JE, et al. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res 1985;45: 2642-9.
14. Cheung NK, Lazarus, H, Miraldi FD, et al. Ganglioside GD2 specific monoclonal antibody 3F8: a phase 1 study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 1987;5:1430-40.
15. Cheung NK, Kushner BH, Yeh SD, et al. 3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study. Int J Oncol 1998;12:1299-306.
16. Cheung NK, Kushner, BH, Cheung IY, et al. Anti-GD2 antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol 1998;16:3053-60.
17. Kushner BH, Kramer K, Cheung NK. Phase II trial of the anti-GD2 monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol 2001;19:4189-94.
18. Kushner BH, Kramer K, Modak S, et al. Anti-GD2 monoclonal antibody 3F8 plus granulocyte-macrophage colony-stimulating factor (GM-CSF) for primary refractory neuroblastoma (NB) in bone marrow (BM) (abstract). J Clin Oncol 2007;25(18S):9502.
19. Kushner BH, Cheung IY, Kramer K, et al. High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy. Pediatr Blood Cancer 2007;48:430-4.
20. Cheung NV, Cheung IY, Kushner BH, et al. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J Clin Oncol 2012;30:3264-70.
21. Cheung NV and Modak S. Oral (123),(134)-4-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin Cancer Res 2002;8:1217-23.
22. Modak S, Kushner BH, Kramer K, et al. Phase I study of the combination of anti-GD2 antibody with 3F8 and barley-derived (1o3),(134)-4-D-glucan for patients with resistant neuroblastoma (abstract). J Clin Oncol 2007;25(18S):9566.
23. Kushner BH, Kramer K, Modak S, Cheung NV. Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study. J Clin Oncol 2011;29:1168-74.
24. Kushner BH. High-dose 3F8/GM-CSF immunotherapy plus 13-cisretinoic acid for primary refractory neuroblastoma in bone marrow. National Cancer Institute: NCT01183897. www.clinicaltrials.gov (accessed 2012 Jul 25).
25. Kushner BH, Cheung NV. High-dose 3F8/GM-CSF immunotherapy plus 13-cis-retinoic acid for consolidation of second greater remission of high-risk neuroblastoma. National Cancer Institute: NCT01183884. www.clinicaltrials.gov (accessed 2012 Jul 25).
26. Basu E. Phase I study of humanized 3F8 monoclonal antibody (Hu3F8) in patients with high-risk neuroblastoma and GD2-positive tumors. National Cancer Institute: NCT 01419834. www.clinicaltrials.gov (accessed 2012 Jul 25).
27. Handgretinger R, Baader P, Dopfer R. A phase 1 study of neuroblastoma with the anti-ganglioside GD2 antibody14. G2a. Cancer Immunol Immunother 1992;35:199-204.
28. Frost JD, Hank JA, Reaman GH, et al. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14. G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Cancer 1997; 80:317-33.
29. Yu AY, Gilman AL, Ozkaynak, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010; 363:1324-34.
30. Handgretinger R, Anderson K, et al. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer 1995;31:261-7.
31. Yu AL, Uttenreuther-Fischer MM, Huang CS, et al. Phase 1 trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol 1998;16:2169-80.
32. Klingebiel T, Bader P, Bares R, et al. Treatment of neuroblastoma stage 4 with 131I-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy. A pilot study. Eur J Cancer 1998;34:1398-402.
33. Simon T, Hero B, Faldum A, et al. Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J Clin Oncol 2004;22:3549-57.
34. Simon T, Hero B, Faldum A, et al. Infants with stage 4 neuroblastoma: the impact of the chimeric anti-GD2 antibody ch14.18 consolidation therapy. Klin Padiatr 2005;217:147-52.
35. Simon T, Hero B, Faldum A, et al. Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. BMC Cancer 2011;11:21.
36. Yu AL, Uttenreuther MM, Kamps A, et al. Combined use of a humanmouse chimeric anti-GD2 (ch14.18) and GM-CSF in the treatment of refractory neuroblastoma. Antibody Immunoconjugate Radiopharmaceut 1995;8:12.
37. Yu AL, Batova A, Alvarado C, et al. Usefulness of a chimeric anti-GD2 (ch14.18) and GM-CSF for refractory neuroblastoma: a POG phase II study. Proc ASCO 1997;16:1846.
38. Ozkaynak MF, Sondel PM, Kraiolo MD, et al. Phase I study of chimeric human/murine anti-ganglioside GD2 monoclonal antibody with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. J Clin Oncol 2000;18:4077-85.
39. Gilman AL, Ozkaynak MF, Matthay KK, et al. Phase I study of ch14.18 with granulocyte-macrophage colony stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group. J Clin Oncol 2009;27:85-91.
40. Navid F, Armstrong M, Barfield RC. Immune therapies for neuroblastoma. Cancer Biol Ther 2009;8:874-82.
41. Navid F, Barfield RC, Handgretinger R, et al. A novel anti-GD2 monoclonal antibody (mAb), hu14.18K322A, in children with refractory or recurrent neuroblastoma: early-phase evaluation (abstract). J Clin Oncol 2011(29S): 9523.
42. Neal ZC, Yang JC, Rakhmilevich AL, et al. Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin-2 therapy. Clin Cancer Res 2004;10:4839-47.
43. Gillies SD, Reilly EB, Lo KM, et al. Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc Natl Acad Sci U S A 1992;89:1428-32.
44. Osenga KL, Hanks JA, Albertini MR, et al. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res 2006;12:1750-9.
45. Shusterman SS, London WB, Gillies SD, et al. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol 2010;28:4969-75.
46. Shusterman SS. Biological therapy, sargramostim, and isotretinoin in treating patients with relapsed or refractory neuroblastoma. National Cancer Institute: NCT01334515. www.clinicaltrials.gov (accessed 2012 Jul 25).
47. Kremens B, Hero B, Esser J, et al. Ocular symptoms in children treated with human-mouse chimeric anti-GD2 mAb ch14.18 for neuroblastoma. Cancer Immunol Immunother 2002;51:107-10.